Pasar al contenido principal

HIPOACUSIA NEUROSENSORIAL Y PROTECCION AUDITIVA: EXPLORANDO LAS BASES GENETICAS Y MOLECULARES PARA DESARROLLAR NUEVAS ESTRATEGIAS TERAPEUTICAS.

PID2023-147347OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2023
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Quinolylnitrone 23 Protects from Auditory Cell Oxidative Injury and Noise-Induced Hearing Loss

  • Murillo-Cuesta, Silvia
  • Contreras, Julio
  • Chioua, Mourad
  • García Montoya, Carmen
  • Rodriguez-de la Rosa, Lourdes
  • Méndez-Grande, Inés
  • Piotrowsk, Dorota G.
  • Głowacka, Iwona E.
  • Varela-Nieto, Isabel
  • Contelles, José-Marco
Oxidative stress is a key pathogenic mechanism in noise-induced hearing loss, occurring when the production of free radicals in the cochlea overwhelms its antioxidant defenses. Thus, antioxidant molecules, including N-acetyl-l-cysteine, acetyl-L-carnitine, resveratrol, HPN-07, and 4-OHPBN nitrones, have been explored as otoprotective agents with limited success. A novel quinolylnitrone derivative QN23 has been shown to suppress oxidative stress in ischemic stroke. In this study, we show that QN23 was not ototoxic and protected from oxidative stress both in vitro in the cochlear HEI-OC1 cell line and in vivo in mice. QN23 increased HEI-OC1 cell survival after H2O2-induced oxidative stress, showing better effectiveness than N-acetyl-l-cysteine. Systemic administration of QN23 in mice was well-tolerated, and significantly reduced acute auditory threshold shifts 1 day postnoise exposure. The protective effects of QN23 were dose- and time-dependent, with optimal results observed when administered twice daily for 3 days, starting 1 h prior to noise exposure. This protection was associated with the duration of the treatment. QN23 normalized the expression of cochlear genes associated with oxidative stress and inflammation, such as Nrf2, Hmox1, Nqo1, Nlrp3, Tnfa, Il1b, Dusp1, and Kim1, among others, counteracting immediate noise-induced molecular alterations. These results suggest that QN23 effectively mitigates cochlear oxidative damage and that early intervention can block critical molecular changes induced by noise, thereby preserving hearing., MINECO/FEDER PID2023–147347OB-I00 (to S.M.-C. and I.V.–N.); 0551-PSL-6-E NITROPROHEAR, CA20121 COST Action/EU-BenBedPhar (to I.V.–N.); CIBERER ERP24P5AC761-ACCI23–19–761 (to S.M.C.); MINA-CM Madrid Innovative Neurotech Alliance P2022/BMD-7236 and Red de Investigación en inflammasoma y piroptosis en enfermedades crónicas y cancer (RED2022–134511-T to J.L.M.C.). S.M.C. and I,M.G. hold CIBER ISCIII postdoctoral and predoctoral contracts, respectively. C.G.M. holds a MINECO PRE2021–10114 predoctoral contract. The synthesis of nitrone TNs was supported by the Medical University of Lodz internal funds (503/3–014–01/503–31–001)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A rare haplotype of the GJD3 gene segregating in familial Meniere’s disease interferes with connexin assembly

  • Escalera-Balsera, Alba
  • Robles-Bolivar, Paula
  • Parra-Pérez, Alberto M.
  • Murillo-Cuesta, Silvia
  • Chow Chua, Han
  • Rodriguez-de la Rosa, Lourdes
  • Contreras, Julio
  • Domarecka, Ewa
  • Amor-Dorado, Juan Carlos
  • Soto Varela, Andrés
  • Varela-Nieto, Isabel
  • Szczepek, Agnieszka J.
  • Gallego-Martínez, Álvaro
  • López-Escamez, Jose A.
[Background] Familial Meniere’s disease (FMD) is a rare polygenic disorder of the inner ear. Mutations in the connexin gene family, which encodes gap junction proteins, can also cause hearing loss, but their role in FMD is largely unknown., [Methods] We retrieved exome sequencing data from 94 individuals in 70 Meniere's disease (MD) families. Through gene burden analysis, we calculated the enrichment of rare variants (allele frequency < 0.05) in connexins genes in FMD individuals compared with the reference population. The connexin monomer and the homomeric connexon structural models were predicted using AlphaFold2 and HDOCK. RT-qPCR and immunofluorescence were done in mice cochleae to identify expression of the mouse ortholog candidate gene Gjd3., [Results] We found an enrichment of rare missense variants in the GJD3 gene when comparing allelic frequencies in FMD (N = 94) with the Spanish reference population (OR = 3.9[1.92–7.91], FDR = 2.36E-03). In the GJD3 sequence, we identified a rare haplotype (TGAGT) composed of two missense, two synonymous, and one downstream variant. This haplotype was found in five individuals with FMD, segregating in three unrelated families with a total of ten individuals; and in another eight MD individuals. GJD3 encodes the gap junction protein delta 3, also known as human connexin 31.9 (Cx31.9). The protein model predicted that the NP_689343.3:p.(His175Tyr) missense variant could modify the interaction between connexins and the connexon assembly, affecting the homotypic GJD3 gap junction between cells. Our studies in mice revealed that Gjd3—encoding Gjd3 or mouse connexin 30.2 (Cx30.2)—was expressed in the organ of Corti and vestibular organs, particularly in the tectorial membrane, the base of inner and outer hair cells and the nerve fibers., [Conclusions] The present results describe a novel association between GJD3 and FMD, providing evidence that FMD is related to changes in the inner ear channels, and supporting a new role of tectorial membrane proteins in MD., JALE has received funds to support research on genetics in Meniere’s disease from The University of Sydney (K7013_B3413 Grant), Asociacion Sindrome de Meniere España (ASMES), and Meniere’s Society, UK. AGM has received funds from the Andalusian Health Department (Grant PI-0266–2021) and from CuresWithinReach and the Knight Family. JALE and AGM have received funds from the Andalusian Government (CECEU 2020, grant code: DOC_01677). IVN and SMC have received funds from PID2020-115274RB-I00 and PID2023-147347OB-I00 funded by MCIN/AEI/https://doi.org/10.13039/501100011033, MICIU/AEI/https://doi.org/10.13039/501100011033 and FEDER, UE; and COST Action CA20113 PROTEOCURE. AMPP was supported by a PhD scholarship from the Regional Ministry of Economic Transformation, Industry, Knowledge and Universities of Junta de Andalucía (Grant number PREDOC2021/00343)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

NLRP3 inflammasome and hearing loss: from mechanisms to therapies

  • Murillo-Cuesta, Silvia
  • Seoane, Elena
  • Cervantes, Blanca
  • Zubeldia, José M.
  • Varela-Nieto, Isabel
The NLRP3 inflammasome, a key component of the innate immune system, has emerged as a central mediator of inflammation-driven sensorineural hearing loss (SNHL). This review synthesizes current evidence on its involvement across a wide spectrum of auditory pathologies, including genetic syndromes such as CAPS and autosomal dominant deafness (DFNA) 34, as well as noise-induced, age-related, drug-induced, and viral hearing loss. Dysregulated activation of NLRP3 in the cochlea leads to the release of proinflammatory cytokines (IL-1B and IL-18) and pyroptotic cell death, contributing to irreversible cochlear damage. Experimental studies have demonstrated that pharmacological inhibition of NLRP3 via agents such as MCC950, oridonin and tranylcypromine can preserve auditory function. Gain-of-function mutations in the NLRP3 gene are frequently associated with both syndromic and nonsyndromic hearing loss, and animal models expressing these mutations replicate cochlear inflammation and hearing deficits, validating their pathogenic role. Clinically, IL-1B signaling blockers such as anakinra and canakinumab have shown efficacy in CAPS patients, stabilizing or improving hearing outcomes. Emerging selective NLRP3 inhibitors, including dapansutrilo and MCC950, are progressing through early-phase clinical trials. Additionally, natural compounds such as piceatannol and oridonin have demonstrated otoprotective effects in preclinical models of noise- and drug-induced hearing loss. Collectively, these findings position the NLRP3 inflammasome as a promising therapeutic target for SNHL. Future translational research should focus on validating NLRP3-targeting compounds in human trials, identifying biomarkers for early diagnosis, and exploring combination therapies that integrate anti-inflammatory, antioxidant, and regenerative strategies. Targeting NLRP3 may ultimately redefine treatment paradigms for preventing or halting progressive hearing loss., This work was funded by CIBERER Grant “ACCI 2023: Nuevas estrategias terapéuticas para el tratamiento de enfermedades raras neurosensoriales (SensoRare)” to SM; MICIU/AEI Grant PID2023–147347OB-I00 to SM and IVN; ISCIII Grant PI21/01325; and Fundación Familia Alonso Grant FFA2024 to ESR. SM holds a CIBERER senior researcher contract., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Molecular predictors of recurrence in vestibular schwannomas: a transcriptomic and RT-qPCR analysis

  • Ruiz-García, Carmen
  • Franco-Caspueñas, Sandra
  • Rodriguez-de la Rosa, Lourdes
  • Martinez-Glez, Víctor
  • Morales-Puebla, José Manuel
  • Varela-Nieto, Isabel
  • Lassaletta, Luis
[Purpose] Vestibular schwannomas (VS) are benign tumors with variable clinical behavior. Recurrence after surgery is uncommon yet sometimes aggressive. Reliable molecular predictors of recurrence are lacking, and the correlation between genotype and phenotype is weak. This study aimed to identify molecular markers associated with recurrence in VS and explore their prognostic potential., [Methods] Retrospective case-control study of patients undergoing VS surgery between 2017 and 2024. RNA-Seq was conducted to identify molecular signatures associated with recurrence, and selected genes were validated using RT-qPCR. Recurrence-free and salvage surgery-free survival were analyzed by the extent of resection., [Results] 23 samples from 22 patients were analyzed, including 7 recurrent and 16 non-recurrent cases. 81 differentially expressed genes were identified in recurrent tumors, with enrichment of the MAPK (FDR = 7.9 × 10⁻⁴) and PI3K/AKT/mTOR (FDR = 0.038) pathways. Eight candidate genes were selected for validation: DCN (FC 4.34); DUSP5 (FC 4.20); CXCL8 (FC 3.25); JUND (FC 3.27); MYC (FC 2.45); MAFF (FC 3.79); SOD3 (FC 2.47) (all upregulated), and TNF (FC 0.16) (downregulated). RT-qPCR confirmed that CXCL8 and TNF were significantly elevated in tumors requiring early salvage surgery and in an NF2-associated Schwannomatosis case. No differences in recurrence-free or salvage surgery-free survival were observed between near-total and subtotal resections., [Conclusion] Recurrent VS exhibit a distinct molecular profile, highlighting IL-8 and TNFα as potential biomarkers and therapeutic targets. These findings support the development of a prognostic panel to guide personalized follow-up and treatment, particularly for high-risk patients. Further studies are needed before clinical implementation., This research was funded by Spanish Ministerio de Ciencia e Innovación/Agencia Estatal de Investigación MCIN/AEI/https://doi.org/10.13039/501100011033 THEARPY-PID2020-115274RB-I00 and Spanish Ministerio de Ciencia, Innovación y Universidades/Agencia Estatal de Investigación MICIU/AEI/https://doi.org/10.13039/501100011033 PROHEAR-PID2023-147347OB-I00 to Isabel Varela-Nieto. The authors thank the support from Madrid Innovative Neurotech Alliance MINA-CM P2022/BMD-7236 consortium and CSIC Rare Diseases Network (RER-Biomed)., Peer reviewed